Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

Autor: Emilie Charton, Jean‐Baptiste Bachet, Pascal Hammel, Jérôme Desramé, Benoist Chibaudel, Romain Cohen, Philippe Debourdeau, Jérome Dauba, Thierry Lecomte, Jean‐François Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guerin‐Meyer, Julien Taieb, Julien Volet, Christophe Louvet, Amélie Anota, Franck Bonnetain

Publikováno v: Cancer Medicine, Vol 8, Iss 11, Pp 5079-5088 (2019)

Abstract Background The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients w

Externí odkaz: https://doaj.org/article/ea9e9d8aac3c4e91a964a297380cb6f7

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

Autor: José Federico González González, Jaime Feliu, P. Vicente, Esther Casado Gonzalez, Guillermo Lopez-Vivanco, Ana Montes, Carmen Garcia Piernavieja, Teresa Macarulla, Irene Gonzalez Cebrian, A. Muñoz, Manuel Valladares-Ayerbes, Mónica Jorge Fernández, Juan Ignacio Delgado-Mingorance, Bartomeu Massuti, Ana Albero, Rebeca Mondéjar Solís, Guillermo Quintero-Aldana

Publikováno v: CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC

[Purpose] To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (> 70 years) with unresectable locally advanced (LAPC) or metastatic pancreatic cancer (mPC) treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a672bc10eeb5fd2ed44a11fb2bed1c7c
https://pubmed.ncbi.nlm.nih.gov/33452559

Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

Autor: Julien Taieb, Jean-Baptiste Bachet, Philippe Debourdeau, Franck Bonnetain, Emilie Charton, Amélie Anota, Pascal Hammel, Christophe Tournigand, Veronique Guerin-Meyer, Romain Cohen, Julien Volet, Jérôme Desramé, Christophe Louvet, Thierry Lecomte, Jérôme Dauba, Thomas Aparicio, Jean-François Seitz, Benoist Chibaudel

Publikováno v: Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5079-5088 (2019)

Background The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c47d1d14a66eb9372de8dbf11f0cf14c
https://pubmed.ncbi.nlm.nih.gov/31314957

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.

Autor: Coomans MB; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands., Dirven L; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Neurology, Haaglanden Medical Center, Den Haag, the Netherlands., Aaronson N; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Baumert BG; Institute of Radiation-Oncology, Kantonsspital Graubünden, Chur, Switzerland.; Department of Radiation Oncology (MAASTRO Clinic), and GROW (School for Oncology and Developmental Biology), Maastricht University Medical Center, Maastricht, the Netherlands., van den Bent M; The Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Bottomley A; Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Brandes AA; Department of Medical Oncology, Azienda USL-IRCCS Institute of Neurological Sciences, Bologna, Italy., Chinot O; Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neuro-Oncologie, Marseille, France., Coens C; Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Gorlia T; European Organization for Research and Treatment of Cancer, Headquarters, Brussels, Belgium., Herrlinger U; Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany., Keime-Guibert F; Groupe Hôpital Pitié-Salpetrière, Assistance Publique, Paris, France., Malmström A; Department of Advanced Home Care and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden., Martinelli F; Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Stupp R; Northwestern University, Feinberg School of Medicine, Chicago, Illinois,USA., Talacchi A; Department of Neurosciences, Azienda Ospedaliera San Giovanni Addolorata , Roma, Italia., Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Wick W; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.; German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany., Reijneveld JC; Department of Neurology and Brain Tumour Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands., Taphoorn MJB; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Neurology, Haaglanden Medical Center, Den Haag, the Netherlands.

Publikováno v: Neuro-oncology [Neuro Oncol] 2022 Dec 01; Vol. 24 (12), pp. 2159-2169.